Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 4/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.48 |
| ▸ | DPP4 | P27487 | 7/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.32 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9853906 | 0.77 | MAPK1 (0.39) | ADRB2ADRB1CYP1A2CYP3A4TSHR | |
| SCHEMBL13974083 | 0.76 | PGR (0.42) | ADRB2ADRB1CYP1A2CYP3A4TSHR | |
| SCHEMBL4627874 | 0.75 | ADRB2 (0.78) | ADRB2ADRB1CYP1A2CYP3A4TSHR | |
| SCHEMBL11643509 | 0.75 | ADRB2 (0.38) | ADRB2ADRB1CYP1A2CYP3A4TSHR | |
| SCHEMBL5165644 | 0.73 | GSK3B (0.54) | ADRB2ADRB1CYP1A2CYP3A4TSHR | |
| SCHEMBL10493941 | 0.73 | GSK3B (0.43) | ADRB2ADRB1CYP1A2CYP3A4TSHR | |
| SCHEMBL29896948 | 0.73 | GSK3B (0.54) | ADRB2ADRB1CYP1A2CYP3A4TSHR | |
| SCHEMBL9821246 | 0.73 | MAPK1 (0.38) | ADRB2ADRB1CYP1A2CYP3A4TSHR | |
| SCHEMBL4391321 | 0.72 | HPGD (0.50) | TSHRDPP4 | |
| SCHEMBL11636886 | 0.72 | ADRB2 (0.42) | ADRB2ADRB1CYP1A2CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120219592-A1 | Use of B-Aminoalcohols in the Treatment of Inflammatory Disorders and Pain | BIOCOPEA LIMITED (GB) | 2012-08-30 | — | — | US | disclosed |
| US-8188150-B2 | Use of beta-aminoalcohols in the treatment of inflammatory disorders and pain | BIOCOPEA LIMITED (GB) | 2012-05-29 | — | — | US | disclosed |
| US-20090306216-A1 | Use of Beta-Aminoalcohols in the Treatment of Inflammatory Disorders and Pain | BIOCOPEA LIMITED (GB) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120219592-A1 | Use of B-Aminoalcohols in the Treatment of Inflammatory Disorders and Pain | OPRL1, HRH3, HRH2 | ADRB2 19/4885ADRB1 36/4885CYP1A2 270/4885 |
| US-20090306216-A1 | Use of Beta-Aminoalcohols in the Treatment of Inflammatory Disorders and Pain | OPRL1, HRH3, NR1H2 | ADRB2 7/4885ADRB1 13/4885CYP1A2 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.